Sunitinib malate for the treatment of pancreatic neuroendocrine tumours
The multikinase inhibitor sunitinib doubled the time to progression in advanced pancreatic neuroendocrine tumours and was approved at the same time as everolimus, giving the disease its first targeted therapies.
Overview
Phase 3 placebo-controlled trial of 171 patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumours randomised to sunitinib 37.5 mg daily or placebo, stopped early after an independent monitoring committee observed more deaths and serious events with placebo.
Median progression-free survival was 11.4 versus 5.5 months (hazard ratio 0.42) with response of 9.3 versus 0 percent; hypertension, hand-foot syndrome and fatigue were the main toxicities.
- Median progression-free survival 11.4 vs 5.5 months; hazard ratio 0.42.
- Objective response 9.3 percent vs 0 percent.
Sunitinib is a standard targeted option for progressive pancreatic neuroendocrine tumours; the choice between it and everolimus is guided by comorbidity and side-effect profile.
- Trial stopped early with 171 of a planned 340 patients, which can overestimate effect.
Similar pages
not linked directly; found by shared links- Key paperRADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
- Key paperCLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.
- Key paperCheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma
Shares Sunitinib, New England Journal of Medicine.
- Key paperKEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma
Shares Sunitinib, New England Journal of Medicine.
- Key paperCABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours
Shares Pancreatic neuroendocrine tumours, New England Journal of Medicine.